Onconova Therapeutics stock has undergone multiple analysts rating changes in the recent past. Onconova Therapeutics Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.
Shares of Onconova Therapeutics traded no change $0.00 on Wednesday, reaching $3.73. 206 shares of the stock traded hands, compared to its average volume of 3752146. Shares of Onconova Therapeutics were trading at $3.73 on Wednesday. The firm’s 50 day moving average is $4.68 and its 200 day moving average is $9.37.Onconova Therapeutics has a 12 month low of $3.62 and a 12 month high of $28.95. While on yearly highs and lows, Onconova Therapeutics’s today has traded high as $3.91 and has touched $3.62 on the downward trend. See More Analyst Rating at: RATING
Onconova Therapeutics Earnings and What to expect:
Onconova Therapeutics last posted its earnings data on August 12th, 2021. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.01. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.04 million. Onconova Therapeutics has generated ($2.10) earnings per share over the last year (($1.47) diluted earnings per share). Earnings for Onconova Therapeutics are expected to grow in the coming year, from ($1.16) to ($1.13) per share. Onconova Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.
Earnings for Onconova Therapeutics are expected to grow in the coming year, from ($1.16) to ($1.13) per share. The P/E ratio of Onconova Therapeutics is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Onconova Therapeutics is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Onconova Therapeutics has a P/B Ratio of 8.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Onconova Therapeutics (NASDAQ:ONTX) Moving Average Technical Analysis
5 day Moving Average is $3.67 And 5 day price change is $0.20 (5.67%) with average volume for 5 day average is 498,960. While technical analysis for average 20 days shows significant difference, 20 day moving average is $4.16 and 20 day price change is -$1.11 (-22.93%) and average 20 day moving volume is 5,528,860. 50 day moving average is $4.68 and 50 day price change is -$1.31 ( -25.99%) and with average volume for 50 days is : 2,361,306. 200 day moving average is $9.37 and 200 day price change is -$3.00 (-44.56%) and with average volume for 200 days is : 2,161,174.
Other owners latest trading in Onconova Therapeutics :
- On 8/25/2021 shares held by Marshall Wace LLP were 24,345 which equates to market value of $0.17M and appx 0.00% owners of Onconova Therapeutics
- On 8/23/2021 shares held by Morgan Stanley were 106,786 which equates to market value of $0.74M and appx 0.00% owners of Onconova Therapeutics
- On 8/18/2021 shares held by Ikarian Capital LLC were 23,226 which equates to market value of $0.16M and appx 0.00% owners of Onconova Therapeutics
- In total Institutional ownership equates to Institutional Ownership Percentage: 15.45% for Onconova Therapeutics
See More Analyst Rating at: RATING